Leukemia & Lymphoma

Article	Citations
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study	86
Impact of SF3B1 mutation in myelofibrosis	48
Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma	41
CRLF2 and IKZF1 abnormalities in childhood hematological malignancies other than B-cell Acute Lymphoblastic Leukemia	34
Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant	33
Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis	27
Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma	25
High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination	24
Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia	23
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma	22
Risk factors for mortality and re-admission of children with hematological malignancies to the intensive care unit due to sepsis	22
Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia	21
CD274 structural variants for guiding treatment with PD-1 blockade in a patient with relapsed/refractory chronic active EBV transformed to NK lymphoma	20
Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management	20
CD69 marks a subpopulation of acute myeloid leukemia with enhanced colony forming capacity and a unique signaling activation state	19
Cigarette smoking is associated with worse prognosis in myelodysplastic syndromes and hematopoietic alterations in murine models	19
Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax	19
Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes	19
MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma	19
Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clini	18
New therapies for angioimmunoblastic T-cell lymphoma: a comprehensive review and analysis	18
Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports	17
Improvement in mortality of hospitalized patients with hematological malignancies in the 2nd wave of COVID-19 in the UK: experience of a large London NHS trust	17
Shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL)	17
Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma	16

Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma	16
Optimization of physician and specialty pharmacy clinical workflow in assessment of risk category and symptom burden in patients with myelofibrosis (MF)	16
XX International workshop on chronic lymphocytic leukemia	15
Transplantation provides superior survival high risk myeloid malignancies in older patients	15
Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma	14
Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia	14
Evaluating early response assessment in extranodal natural killer/T-cell lymphoma by analyzing ΔSUVlbm between baseline and interim 18 F-FDG PET/CT scans	14
Organ toxicities associated with chimeric antigen receptor T-cell therapy	13
The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia	13
Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study	13
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents	13
The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis	13
Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with acute myeloid leukemia meeting ineligibility criteria for high intensity chemotherapy	13
Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study	12
Making the case for the case report – informing physicians of intracranial hypertension as an adverse event in tyrosine kinase inhibitor treated chronic myeloid leukemia patients	12
Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor – a retrospective, single center study	12
Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma	12
NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma—opportunities for therapy	12
Management of relapsed/refractory mantle cell lymphoma	12
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy	12
Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?	12
Targeting mitochondrial metabolism in acute myeloid leukemia	12
Serum lipid trajectories in the years before a lymphoma diagnosis	12
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation	12
CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study	12
The inherited genetic contribution and polygenic risk score for risk of CLL and MBL: a narrative review	12
Rare HNRNPH1::ERG rearrangement in a case of de novo pediatric AML and review of cases	12
Analysis of albumin as a prognostic factor in HHV-8/HIV-negative Castleman disease from a multicenter study	12
CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors	12
Indolent B-cell non-Hodgkin lymphomas in children: high association with inborn errors of immunity	12
Successful treatment with belantamab mafodotin in a heavily pretreated patient with multiple myeloma and liver extramedullary disease	11
Olverembatinib in relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: a study of 5 cases	11
Richter transformation – retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group	11
Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine	11
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma	11
MicroRΝΑ analysis in patients with myelodysplastic neoplasms. Possible implications in risk stratification	11
Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma	11
Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplanta	11
Interferon maintenance for prevention of relapse in favorable risk AML?	11
A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma	11
Infections in secondary immunodeficiency patients treated with Privigen®or Hizentra®: a retrospective US administrative claims study in patients with hematological malignancies	11
Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience	11
State-wise disparities and temporal trends in acute myeloid leukemia (AML) in the United States of America (USA)	10
Chemotherapy-free approach with arsenic trioxide and all-trans retinoic acid in children with acute promyelocytic leukemia	10
Progressive eosinophilia and STAT5B mutation acquisition in AML treated with azacitidine and venetoclax	10
Correction	10
Evaluation of non-research and research industry payments to pediatric hematologist/oncologists in the United States between 2013 and 2021	10
Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic	10
CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges	10
Mutational landscape in Waldenström macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice	10

Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia	10
Transforming growth factor beta receptor type I (TGF-βRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS	10
Expanding the phenotypic spectrum of DDX41-related myeloid neoplasms: a case of mature plasmacytoid dendritic cell proliferation associated with acute myeloid leukemia with germline DDX41 mutation	10
PHi-RACE: PGIMER in-house rapid & cost effective classifier for the detection of BCR-ABL1 -like acute lymphoblastic leukaemia in Indian patients	10
Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression	10
The Prognostic Nutritional Index (PNI) is an independent predictor of overall survival in older patients with follicular lymphoma	9
Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia	9
Megakaryocyte centrosomal and Golgi structural perturbations in patients with primary myelofibrosis and with RUNX1 germline mutation	9
Lymphocyte HLA-DR/CD-38 co-expression correlates with Hodgkin lymphoma cell cytotoxicity in vitro independent of PD-1/PD1-L pathway	9
The International Prognostic Score and HIV status predict red cell concentrate transfusion needs in Hodgkin lymphoma	9
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia	9
Prediction for sustained deep molecular response for treatment-free remission	9
Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation	9
The characterization and the impact of CSF pleocytosis during blinatumomab therapy for adult acute lymphoblastic leukemia	9
The diagnosis of Burkitt lymphoma: how do pathologists apply criteria in daily practice?	9
Prospects for liquid biopsy approaches in lymphomas	9
Achievement of durable remission of relapsed/refractory acute myeloid leukemia in a child using venetoclax monotherapy	9
Low-risk relapsed acute lymphoblastic leukemia in children and young adults: what have we learnt and what’s next?	9
Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia	9
[ 211 At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignancies	9
The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics	9
A PET in a time of need: toward early PET-adapted therapy in DLBCL in first relapse	9
Off-label use of recombinant activated factor VII in hemophagocytic lymphohistiocytosis patients with major bleeding	9
A single-center analysis of patients with extranodal marginal zone lymphoma of the breast	9
Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab	9
Ph-like acute lymphoblastic leukemia in adults: understanding pathogenesis, improving outcomes, and future directions for therapy	9
MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis	9
Sun protection behaviors among adult survivors receiving hematopoietic cell transplantation: a cross-sectional survey of a single institution in Japan	9
COVID-19 antibody titers after tixagevimab–cilgavimab injection in patients with hematologic diseases; a single-center, prospective study	9
Well-differentiated systemic mastocytosis with associated myeloid sarcoma and myelodysplastic syndrome: Diagnostic challenges of an underrecognized entity	9
Prephase steroid use and association with dose delays and outcomes in a real-world cohort of older adults treated for diffuse large B-cell lymphoma	9
Unmanipulated haploidentical donor and matched unrelated donor hematopoietic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria: a single-center study	9
The diagnostic profile of rare acute myelomegakaryoblastic leukemia	9
Impact of chronic graft- versus -host disease on non-relapse mortality and survival	9
Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir	9
Challenging diagnosis of chronic myelomonocytic leukemia (CMML) in a patient with Takayasu arteritis: case report	8
Effectiveness and safety of leukapheresis in hyperleukocytic leukemias: a retrospective multicenter study	8
A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma	8
Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phase	8
TP53 -altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs	8
Clinicopathologic and genetic evaluation of B-lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21) in adult patients	8
CALR -mutated myeloproliferative neoplasms	8
Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression	8
Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma	8
Two recurrent types of IGH ::5′ BCL2 breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the	8
Intake of benzodiazepines in treatment naïve chronic lymphocytic leukemia patients is associate with a shorter time to first treatment	8
Role of the splenic microenvironment in chronic lymphocytic leukemia development in Eµ-TCL1 transgenic mice	8
Ixazomib-induced thrombotic microangiopathy resolving without complement pathway inhibition: a case report	8
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma	8
Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy – a retrospective cohort stud	8
Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen	8
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison	8
Fatigue – a substantial problem in hematology, but what can be done?	8
Clinical characteristics and outcomes of Brazilian patients with duodenal-type follicular lymphoma: a multicenter retrospective study	8
Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation	7
Patterns of care and outcomes of early stage I–II Hodgkin lymphoma treated with or without radiation therapy	7
Successful treatment of acquired von Willebrand syndrome secondary to low-grade CLL with rituximab and venetoclax	7
Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin ( NPM1 ) gene mutation subtypes: a single-center experience and re	7
Optimizing pegaspargase therapy in patients with hypersensitivity reactions	7
Mitigating time toxicity in lymphoma and multiple myeloma	7
Lenalidomide, rituximab (R 2 ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma	7
Improved overall survival over time in advanced stage mycosis fungoides: a cross-sectional study	7
Prevalence and clinicopathological features of incidentally detected TRBC1-dim populations in peripheral blood flow cytometry	7
Allogeneic stem cell transplant outcomes between TBI-containing reduced intensity and myeloablative conditioning regimens for ALL in complete remission	7
Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas	7
HHV8-Negative Effusion-Based lymphoma in a patient with recurrent HCV hepatitis status post liver transplantation	7
Impact of the addition of rituximab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia	7
Inter-racial genetic differences in myelofibrosis: a diverse inner-city center analysis	7
Progressive TP53 inactivation in an aggressive splenic diffuse red pulp small B-cell lymphoma	7
Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin	7
Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach	7
Measurable residual disease dynamics holding prognostic significance in pediatric patients with RUNX1::RUNX1T1 -positive AML: results from AML-CAMS serial trials	7
Response to trametinib of two pediatric myeloid malignancies cases harboring RAS mutation and monosomy 7	7
Familial aspects of multiple myeloma and Waldenström macroglobulinemia: understanding the predisposition in relatives and the importance of early diagnosis	7
The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study	7
Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients	7
Consistency of the efficacy of immunotherapy with histamine dihydrochloride and low-dose interleukin-2 for relapse prevention in acute myeloid leukemia	7
Determinants of ten-year overall survival of acute myeloid leukemia: a large national cancer database analysis	7
Indolent relapse after initial aggressive B-cell lymphoma: a single institution experience in the rituximab era	7
Leukocytosis and MPNs: Where do we stand?	7

A Shared Care Model between community and transplant centers facilitates access to allogeneic and autologous transplantation	7
White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia	7
Emerging drug profile: JAK inhibitors	7
Effects of fludarabine dosage on transplant-related outcomes in hematopoietic stem cell transplantation	7
CCND2 mutations in atypical chronic myeloid leukemia: a report of two cases	7
Relapsed and refractory peripheral T-cell lymphoma; treatment, challenges and future perspectives	7
Distinct immune-response profile of Richter transformation chronic lymphocytic leukemia (CLL), defined by high expression of PD1, LAG3, TIM3 and IL-10	6
A de novo germline RUNX1 variant preceding development of concurrent T-lymphoblastic leukemia and myelodysplastic syndrome	6
Comparison of CALGB 10403 and HyperCVAD in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia in adults ≥40 years old	6
Allogeneic transplant graft source – conditioning – GVHD prophylaxis: don’t mix and match!	6
A case of testicular diffuse large B-cell lymphoma with late relapse in the skin: the critical role of comparative phenotypic, clonality, and cytogenetic testing	6
Normal and malignant cells are homogeneously distributed in the bone marrow of children	6
Myeloid/lymphoid neoplasm with a novel cryptic RBPMS::FGFR1 rearrangement presenting as de novo acute leukemias	6
Precision and strategic targeting of novel mutation-specific vulnerabilities in acute myeloid leukemia: the semi-centennial of 7 + 3	6
Correction	6
Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation	6
Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era – forgotten but not gone	6
Genomic landscape of T-large granular lymphocyte leukemia and chronic lymphoproliferative disorder of NK cells: a single institution experience	6
KLF2 double variants (C274Y and H210N) in a splenic B-cell lymphoma/leukemia: diagnostic insights into splenic marginal zone lymphoma and mechanistic implications	6
Sequential occurrence of chronic myeloproliferative and lymphoproliferative neoplasms: a collaborative retrospective study by pH-negative MPN latial group	6
Glycated hemoglobin (HbA1c) and thrombotic risk in polycythemia vera and essential thrombocythemia	6
Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the ‘RTL’ (regional Tuscan lymphoma network)	6
Lower intensity regimens for acute myeloid leukemia: opportunities and challenges	6
Follicular lymphoma of the lower female genital tract: an indolent and localized extranodal follicular lymphoma with mutation of TNFRSF14	6
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma	6
Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance	6
Polymerase chain reaction in the diagnosis of invasive aspergillosis: approaches for appropriate use	6
Hepatic Veno-occlusive disease (VOD) in multiple myeloma patient receiving Belantamab Mafodotin	6
Evaluation of a safe neutrophil count for cessation of intravenous antibiotics and early hospital discharge in stable, afebrile patients recovering after acute myeloid leukemia therapy or an autograft	6
CD5- B-cell lymphocytic leukemia –a diagnostic exclusion of splenic B-cell leukemia with prominent nuclei challenging current international consensus	6
Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation	6
COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies	6
Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive	6
Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function	6
Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse	6
Pre-diagnostic serum concentrations of free light chains and risk of non-Hodgkin lymphoma in a population-based prospective study	6
Characterization of the calcineurin inhibitor pain syndrome in patients undergoing allogeneic hematopoietic cell transplantation	6
Epstein-Barr virus copy number in peripheral blood mononuclear cells predicts prognosis in diffuse large B cell lymphoma	6
Tagraxofusp as first-line treatment for blastic plasmacytoid dendritic cell neoplasm	6
Correction	6
Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group	6
Mutational patterns in therapy-related acute lymphoblastic leukemia subgroups: one step closer to unveiling the genetic odyssey	6
Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma	6
Performance of the frailty index in predicting complete remission, intensive care unit admission, and overall mortality in older and younger patients with acute myeloid leukemia receiving intensive ch	6
Preclinical and clinical evaluation of Buparlisib (BKM120) in recurrent/refractory Central Nervous System Lymphoma	6
A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia	6
Labile CD22 and CD19 expression in a case of Philadelphia chromosome-like acute lymphoblastic leukemia	6
Moving beyond traditional clinical trial endpoints: patient-reported outcomes illuminate the patient experience of novel AML therapies	6
Insurance-based disparities impact survival outcomes in Waldenström macroglobulinemia within the United States	6
Factors affecting treatment decisions for lower-risk myelodysplastic syndromes across practice settings	5
Elicitation of societal preferences for chronic lymphocytic leukemia’s treatments: a discrete choice experiment	5
Breakthrough COVID-19 is mild in vaccinated patients with hematological malignancy receiving tixagevimab-cilgavimab as pre-exposure prophylaxis	5
Effectiveness of prophylactic intrathecal chemotherapy and risk factors of central nervous system relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia	5
Be on guard: longer monitoring for very–late onset hepatitis B virus reactivation after chemo-immunotherapy?	5
Adapted risk stratification and intensive chemotherapy abrogate the poor prognosis of pediatric B acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21): a National	5
Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study	5
Calcific tendinopathy: an unexpected side effect of tyrosine kinase inhibitor?	5
Treatment of relapsed and refractory Waldenstrom Macroglobulinemia	5
EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort	5
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma	5
Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review	5
The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing	5
Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data	5
Flow cytometry is a sensitive technique to assess marrow involvement by B cell non-Hodgkins lymphoma	5
The challenge of non-transplant eligible, newly diagnosed multiple myeloma	5
Fish evaluation of additional cytogenetic aberrations and hyperdiploidy in childhood Burkitt lymphoma	5
Risk factors for influenza virus infection in patients with hematological disease	5
Prognostic factors and outcomes of infant acute lymphoblastic leukemia (ALL), hypodiploid ALL, and mixed-phenotype acute leukemia (MPAL) in Canada: a report from CYP-C	5
Persistent parvovirus B19 infection in a heavily pretreated lymphoma patient receiving mosunetuzumab	5
Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort study	5
Validation of SAPS 3 for predicting in-hospital mortality in patients with haematological malignancy requiring ICU management	5
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia	5
Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study	5
Chronic lymphocytic leukemia transdifferentiated to blastic neoplasm with T/plasmacytoid dendritic cell immunophenotype	5
EZH2 inhibitor DZNep blocks cell proliferation of GCB-DLBCL cells by upregulating p16	5
Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma	5
COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study	5
The pretreatment Controlling Nutritional Status score is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma	5
Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies	5
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study	5
Consecutive day dosing of high-dose cytarabine consolidation over 3 days is resource-efficient and safe in older adult patients with acute myeloid leukemia	5
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline ‘chemotherapy-free’ therapy	5
RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL	5
Attempted desensitization to calaspargase pegol: a familiar approach to a new problem	5
Real-world treatment patterns for patients with newly diagnosed multiple myeloma in Alberta, Canada	5
Race (and ethnicity) matters in myelodysplastic syndromes	5
Prognostic assessment value of immune escape-related genes in patients with acute myeloid leukemia	5
TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression	5
Follicular lymphoma: an update on biology and optimal therapy	5
Circulating serum microRNAs as biomarkers of drug resistance in multiple myeloma patients treated with bortezomib-based regimens – pilot study	5
Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome	5
Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry	5
Pneumocystis jirovecii pneumonia with use of brentuximab vedotin in treatment-naïve Hodgkin lymphoma	5
Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination	5
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI)	5